Table 1.
Comparison of the clinical cases reported in the literature.
| Glioblastoma at the same site | Supratentorial glioblastoma | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Authors, year | Schmidbauer et al., 1987 (5) | Yang et al., 2005 (7) | Gessi et al., 2008 (8) | Hamasaki et al., 2010 (9) | Madden et al. (series), 2010 (18) | Martin et al., 2012 (10) | Our case, 2021 | Pearl et al., 1980 (11) | Wang et al., 2018 (12) |
| Onset age (years), gender | 13, M | 5, M | 7, M | 5, M | 5, M | 9, M | 27, M | 5, M | 4, M |
| Surgery | Total removal | Gross total resection | Total removal | Gross total resection | Gross total resection | Gross total resection | No data | Subtotal rasection | Total resection |
| Radiation dose (Gy), whole brain | 60 | 36 | 20.8 | 40 | 23.4 | 23.4 | Yes (no data) | 30 | 30.6 |
| Radiation dose (Gy), posterior fossa | – | 20 | 59.8 | – | 55.8 | 55.8 | No data | 10 | 54 |
| Radiation dose, spinal cord (Gy) | – | 24 | – | 30.5 | 23.4 | 23.4 | Yes (no data) | 20 | 30.6 |
| Chemotherapy | Vincristine and CCNU | Eight-in-one regimen (solumedrol, vincristine, lomustine, procarbazine, hydroxyurea, cisplatin, cytoxan, and cytosine arabinoside) | Methotrexate, etoposide, cyclophosphamide, carboplatinum | No chemotherapy | Pre-RT: vincristine. Post-RT: lomustine, cisplatin, and vincristine Or cyclophosphamide, cisplatin, and vincristine | CCNU (lomustine), cisplatin and vincristine | Yes (no data) | No data | No |
| Latency of recurrence (years) | 6 | 10 | 8 | 35 | 6 | 5 | 29 | 13 | 8 |
| Surgery | Radical resection | Subtotal removal | Partial removal | Partial removal | Tumor resection | No surgery | Subtotal resection | Left occipital lobectomy | Yes, resection |
| Histology of biopsy | GBM | Glioblastoma | Glioblastoma | GBM | GBM | Postmortem biopsy: GBM | GBM with rhabdoid characteristics | GBM | GBM with rhabdoid characteristics |
| Radiation for GBM (RT) | 55 Gy at the PF | No | No | 50 Gy | No | No | No | 30 Gy to whole brain, 15 boosts on the PF and 30 for the spinal cord | No |
| Chemotherapy for GBM | Yes (no data) | Tamoxifen, irinotecan, cisplatin, and 13-cis-retinoic acid | Temozolomide | ACNU, procarbazine, and vincristine | No chemotherapy | Yes (no data) | Temozolomide | CCNU, procarbazine, and vincristine | Nimotuzumab, bevacizumab, and irinotecan |
| Follow-up | 2 years, good evolution | 1 year | No data | 1 year | 5 months, deterioration | 4 months | 11 months, good evolution | 2 years, progressive worsening | 1 y, progressive worsening |
| Outcome | Death, 2 years | Death, 1 year | No data | Death, 1 year | Death, 5 months | Death, 4 months | Death, 11 months | Death, 2 years | Death, 1 year |
GBM, glioblastoma multiforme; ACNU, 1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-3-(2-cholroethyl)-3-nitrosourea hydrochloride; PF, posterior fossa; RT, radiotherapy.